Allergan

What Allergan does

Allergan, originally founded in 1950 as a small eye-care company, operated as a global specialty pharmaceutical and medical aesthetics company before being acquired by AbbVie in March 2020 for approximately $63 billion. Pre-acquisition, under David Pyott's 17-year tenure, Allergan grew from approximately $1 billion in revenue to approximately $7 billion by expanding into aesthetics, eye care, immunology, and oncology products. Today Allergan is a wholly-owned subsidiary of AbbVie, operating under the Allergan Aesthetics and Allergan Eye Care brands within a combined organization of approximately 50,000 employees.

Allergan's product portfolio centers on BOTOX, the original botulinum toxin type A product that pioneered the medical aesthetics industry, and the JUVÉDERM collection of FDA-approved hyaluronic acid injectable dermal fillers used for facial volume restoration, wrinkle smoothing, and lip enhancement, with the September 2023-launched SKINVIVE by JUVÉDERM extending the franchise. The broader portfolio spans over 30 brands treating more than 60 conditions across oncology, immunology, aesthetics, and eye care. Distribution relies on an enterprise field sales model reaching aesthetic clinics, dermatology centers, ophthalmology practices, spasticity treatment providers, and hospitals globally.

Revenue is generated through one-time license/injection-based transactions administered by licensed healthcare providers. JUVÉDERM fillers are priced at approximately $450-$650 per syringe in the United States with results lasting 6 to 18 months per treatment cycle. Allergan plc was Irish-domiciled prior to the acquisition; Allergan Sales, LLC operates as a US subsidiary for legal and commercial purposes. The company has engaged in active patent litigation and defense (Restasis, eyelash growth drug, Botox-related disputes) and most recently terminated a February 2021 development agreement with CollPlant Biotechnologies for a photocurable dermal filler in April 2026.

Name

Allergan

Legal name

Allergan plc

Website

https://allergan.com

Company type

Private

Founded year

1950

Operating status

Acquired

Headcount range

5,001–10,000 employees

Short description

Allergan, a wholly-owned AbbVie subsidiary since 2020, is a global specialty pharmaceutical and medical aesthetics company offering BOTOX, the JUVÉDERM filler collection, and eye care products to healthcare providers, aesthetic clinics, dermatologists, and ophthalmologists worldwide.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals and Medical Aesthetics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industry

Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Medical aesthetics products
• Pharmaceutical therapeutics
• Dermal filler injectables
• Ophthalmology treatments
• Botulinum toxin products

Headquarters

HQ city

Madison

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Pharmaceutical Products: Revenue from prescription pharmaceutical products across multiple therapeutic areas including immunology, oncology, aesthetics, and eye care, with over 30+ brands treating 60+ conditions
2. Medical Aesthetics: Revenue from aesthetic products including BOTOX, JUVÉDERM fillers, and other aesthetic devices and treatments

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Allergan, now part of AbbVie, develops and commercializes pharmaceutical and medical aesthetics products across more than 30 brands treating over 60 conditions. Its portfolio centers on botulinum toxin (BOTOX), hyaluronic acid dermal fillers (JUVÉDERM collection including SKINVIVE by JUVÉDERM), specialty medicines in immunology and oncology, and ophthalmology treatments, sold to healthcare providers, aesthetic clinics, and hospitals globally.

Product overview

Allergan, now part of AbbVie, offers over 30+ brands treating 60+ conditions across oncology, immunology, aesthetics, and eye care. The company's aesthetics portfolio centers on its iconic Botox franchise and the Juvéderm collection of hyaluronic acid dermal fillers, including the recently FDA-approved SKINVIVE by JUVÉDERM.

Differentiator

Problem solved

Functional benefit

Brands

• JUVÉDERM: FDA-approved injectable dermal fillers collection made with hyaluronic acid to restore facial volume, smooth wrinkles, and enhance lips. Multiple formulations tailored for different facial areas with results lasting 6 to 18 months.
• BOTOX
• BOTOX Cosmetic

Products and services

• BOTOX
• JUVÉDERM Collection
• SKINVIVE by JUVÉDERM
• BOTOX Cosmetic

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor.

• CollPlant BiotechnologiesminorStrategic or Co-development Partner · 1 February 2021Development and global commercialization agreement for dermal and soft tissue filler products using CollPlant's photocurable dermal filler platform. AbbVie through its subsidiary Allergan Industrie SAS terminated this agreement in April 2026, leading CollPlant to implement cost-reduction measures including approximately 50% workforce reduction.
• Various Generic Pharmaceutical CompaniesminorOthersAllergan has been involved in patent litigation defending its drug portfolios including the use of tribal immunity strategies, as documented in DrugPatentWatch analysis of pharmaceutical patent litigation costs.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Prollenium Medical Technologies:
• Crown Laboratories: Crown Laboratories (with its SkinMedica brand) competes in the medical aesthetics and professional skincare space, offering complementary skin rejuvenation treatments alongside Allergan's aesthetics portfolio.
• Hugel: Hugel is a South Korea-based botulinum toxin manufacturer (Botulax/Letybo) expanding globally as a lower-priced competitor to BOTOX in aesthetics and therapeutics — emerging as a meaningful threat in price-sensitive markets.

Direct peers

• Galderma: Galderma is the leading direct competitor to Allergan Aesthetics, marketing the Dysport botulinum toxin, Restylane hyaluronic acid fillers, and Sculptra — directly contesting BOTOX and JUVÉDERM in aesthetic clinics worldwide.
• Revance Therapeutics: Revance developed DaxibotulinumtoxinA (Daxxify), a long-duration neuromodulator, and the RHA Collection of hyaluronic acid fillers — directly competing with both BOTOX and JUVÉDERM in medical aesthetics.
• Evolus: Evolus markets Jeuveau (prabotulinumtoxinA), a competing botulinum toxin type A approved for glabellar lines, directly targeting Allergan's BOTOX Cosmetic in the aesthetics channel.
• Merz Aesthetics: Merz Aesthetics competes head-to-head with Allergan in medical aesthetics, offering Xeomin (botulinum toxin), the Radiesse and Belotero filler lines, and Ultherapy — a direct portfolio overlap in both toxins and dermal fillers.
• Ipsen: Ipsen manufactures Dysport (abobotulinumtoxinA), a leading competitor to BOTOX in both aesthetic and therapeutic indications (spasticity, cervical dystonia), and partners with Galderma for aesthetics distribution.

Broad incumbents

• AbbVie: AbbVie is Allergan's parent company and the broad incumbent acquirer that consolidates Allergan's aesthetics and eye care franchises alongside Humira, Skyrizi, and Rinvoq in immunology and oncology.

Others

• Teva Pharmaceutical Industries: Teva acquired Allergan's Actavis Generics unit for $40.5B in 2015, creating a former corporate relationship; Teva remains a peer in the broader specialty and generics pharmaceutical landscape.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Allergan
• YouTubeyoutube.com/user/AbbVie
• Facebookfacebook.com/AbbVieGlobal
• LinkedInlinkedin.com/company/allergan
• Instagraminstagram.com/abbvie/?hl=en

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A31 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allergan